PlainRecalls
CriticalClass ITerminated

FDA Drug recall · Reported March 14, 2018

Bella Capsules, 600mg, 30-count bottles, Manufactured for: Bella All Natural 304 E 11th Street, Los Angeles, CA 90015

Marketed Without An Approved NDA/ANDA: This product contains undeclared sibutramine. The presence of sibutramine, a previously approved controlled substance that was withdrawn fro…

Recall #
D-0593-2018
Affected scope
32 bottles
Initiated
February 14, 2018
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

Bella All Natural recalled Bella Capsules, 600mg, 30-count bottles, Manufactured for: Bella All Natural 304 E 11th S… — a critical-severity action.

Bella Capsules, 600mg, 30-count bottles, Manufactured for: Bella All Natural 304 E 11th S… was recalled by Bella All Natural in March 14, 2018. Reason: Marketed Without An Approved NDA/ANDA: This product contains undeclared sibutramine. The presence of sibutram…. Check the official notice for the remedy. Verify recall #D-0593-2018 with the FDA Drug before acting.

The recall

Bella All Natural issued this critical-severity FDA Drug recall — Marketed Without An Approved NDA/ANDA: This product contains undeclared sibutramine. The presence of sibutram….

Critical
severity level
Class I
classification
March 14, 2018
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0593-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0593-2018) was formally reported on March 14, 2018, with the manufacturer initiating the action on February 14, 2018. It is classified under Critical severity (Class I), with a current status of Terminated. Bella All Natural is listed as the recalling firm, operating out of Los Angeles, CA. Federal records list the affected scope as 32 bottles.

The documented reason for this recall is: Marketed Without An Approved NDA/ANDA: This product contains undeclared sibutramine. The presence of sibutramine, a previously approved controlled substance that was withdrawn from the U.S. market in October 2010 due to… Distribution data in the federal record shows the product reached: Product was distributed in California to online customers and retail stores.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug — clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category — 14,048 drugs & medications recalls on record

-50005001,0001,5002,000 20052009201220152018202120242026 216

Where this recall sits in the database

Severity2366872097High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 100,165 recalls in the database, 23,668 are high severity, 72,097 moderate, and 4,400 low. This recall is classified high severity.

Counts reflect market size and reporting activity, not inherent danger — we do not rank products by risk from raw recall volume.

Severity

Critical

Affected scope

32 bottles

Related Recalls

6

5 from same agency

Product description

Bella Capsules, 600mg, 30-count bottles, Manufactured for: Bella All Natural 304 E 11th Street, Los Angeles, CA 90015

Reason for recall

Marketed Without An Approved NDA/ANDA: This product contains undeclared sibutramine. The presence of sibutramine, a previously approved controlled substance that was withdrawn from the U.S. market in October 2010 due to safety concerns, in this tainted product renders it an unapproved drug for which safety and efficacy have not been established and therefore subject to recall.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Critical (Class I)
Status Terminated
Recall number D-0593-2018
Date reported March 14, 2018
Date initiated February 14, 2018
Recalling firm Bella All Natural
Firm location Los Angeles, CA
Affected scope 32 bottles
Distribution Product was distributed in California to online customers and retail stores.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0593-2018) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting — recall details can be updated.
  • This is a Class I (high-risk) recall — stop using the product immediately and follow the disposal or return instructions. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Bella Capsules, 600mg, 30-count bottles, Manufactured for: Bella All Natural 304 E 11th Street, Los Angeles, CA 90015. Recalled by Bella All Natural. Units affected: 32 bottles.
Why was this product recalled?
Marketed Without An Approved NDA/ANDA: This product contains undeclared sibutramine. The presence of sibutramine, a previously approved controlled substance that was withdrawn from the U.S. market in October 2010 due to safety concerns, in this tainted product renders it an unapproved drug for which safety and efficacy have not been established and therefore subject to recall.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 14, 2018. Severity: Critical. Recall number: D-0593-2018.
Where was the recalled product distributed?
Distribution: Product was distributed in California to online customers and retail stores..
How do I check if my product is affected by a recall?
Check the product description and recall number (D-0593-2018) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category — useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with Nicotine Transdermal System Patch, 14 mg, 14 patches per bo… →

Browse all Drugs & Medications recalls →

Data Sources

Source: FDA, CPSC, and NHTSA federal recall databases. This recall: FDA Drug, reported March 14, 2018.

  • Source: FDA — Food and Drug Administration, openFDA Enforcement API (food, drug, and medical device recalls)
  • Source: CPSC — Consumer Product Safety Commission Recalls API (consumer product recalls and hazards)
  • Source: NHTSA — National Highway Traffic Safety Administration Recalls API (vehicle safety recalls)

Recall information is sourced from official federal agency databases. Always verify recall details with the issuing agency for the most current status. This information is for research and awareness purposes only.

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records — no number is typed in by an editor. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of June 2026.